VivoSight detects 48% more basal cell carcinomas (BCCs) compared to clinical observation
DOTmed issues an article on results from the US BCC study
Clinical trials in the U.S. have now shown that multi-beam Optical Coherence Tomography (‘OCT’) technology, may make diagnosis cut-free and immediate, according to English medical device company Michelson Diagnostics. In a multi-center study, its VivoSight OCT scanner, has been shown to significantly improve diagnosis of basal-cell carcinoma at an earlier stage and cut biopsies by 36 percent. The paper about this study appeared in the Journal of Clinical and Aesthetic Dermatology.